Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999–2018
| Autor: | Karen A Norris, Emily Rayens, José F. Cordero |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology HIV Infections Sepsis 03 medical and health sciences Diabetes mellitus medicine Humans Intensive care medicine Mortality trends business.industry Incidence Incidence (epidemiology) Mycotic disease Cancer medicine.disease United States Major Articles and Commentaries Fungal disease 030104 developmental biology Infectious Diseases Mycoses Cohort Morbidity business Invasive Fungal Infections |
| Zdroj: | Clin Infect Dis |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | Background Invasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections. Methods We analyzed data from the National Vital Statistics System from 1999 through 2018 to estimate the mortality attributed to risk conditions and related fungal disease. Results The number of risk conditions associated with fungal disease is steadily rising in the United States, with 1 047 422 diagnoses at time of death in 2018. While fungal disease decreased substantially from 1999 to 2010, primarily due to the control of human immunodeficiency virus (HIV) infection, the number of deaths with fungal diagnosis has increased in the non-HIV cohort, with significant increases in patients with diabetes, cancer, immunosuppressive disorders, or sepsis. Conclusions The landscape of individuals at risk for serious fungal diseases is changing, with a continued decline in HIV-associated incidence but increased diagnoses in patients with cancer, sepsis, immunosuppressive disorders, and influenza. Additionally, there is an overall increase in the number of fungal infections in recent years, indicating a failure to control fungal disease mortality in these new immunocompromised cohorts. Improvement in the prevention and management of fungal diseases is needed to control morbidity and mortality in the rising number of immunocompromised and at-risk patients in the United States. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|